Thalassemia
Clinical Snapshot
Thalassemia is not one disease but a heterogeneous group of inherited disorders of hemoglobin production — a genuinely different pathophysiology from sickle cell disease's single structural hemoglobin variant (HbS) that polymerizes and deforms red cells. In thalassemia, mutations reduce or abolish production of a normal-structure globin chain itself, leaving the other chain type in relative excess.[1]
Alpha-thalassemia is caused by reduced or absent alpha-globin chain production; each person typically has four alpha-globin genes. Losing one gene (silent carrier) or two genes (alpha-thalassemia minor/trait) is usually clinically silent; losing three genes causes Hemoglobin H (HbH) disease — a form of non-transfusion-dependent thalassemia (NTDT) with moderate hemolytic anemia; losing all four genes causes Hb Barts hydrops fetalis, which is fatal in utero without aggressive intrauterine transfusion.[1]
Beta-thalassemia is caused by reduced or absent beta-globin chain production; each person typically has two beta-globin genes, and the disease is inherited in an autosomal recessive pattern. The severity spectrum runs from beta-thalassemia trait/carrier (one mutated gene, mild asymptomatic microcytosis) through beta-thalassemia intermedia (NTDT) (compound heterozygous states for milder mutations, or variants such as HbE/beta-thalassemia or delta-beta-thalassemia, sometimes needing occasional transfusion) to beta-thalassemia major (transfusion-dependent thalassemia, TDT) — homozygous or compound heterozygous mutations that abolish beta-globin production, causing severe anemia that necessitates regular red cell transfusion beginning in infancy.[1]
The unifying pathophysiology across every form is globin chain imbalance: the excess, unpaired chain precipitates within erythroid precursors, damaging red cell membranes and organelles and triggering both premature intramedullary destruction (ineffective erythropoiesis) and shortened peripheral red cell survival (hemolysis). The body's compensatory response — erythroid marrow hyperplasia — can reach 10-20 times normal in inadequately treated thalassemia major, and this compensatory marrow expansion is itself the direct cause of the disease's classic bony and facial deformities if regular transfusion does not adequately suppress it (see Recognize the Condition and Red Flags & Refer).[2]
Thalassemia is genuinely relevant to Canadian practice: the Mediterranean, Middle East, North Africa, India, Southeast Asia, and China together account for roughly 95% of the world's thalassemia births, and ongoing migration to Canada from these regions means equitable access to comprehensive thalassemia care is an active, evolving challenge across the country.[1]
Recognize the Condition
Typical presentation by severity category
The same underlying globin-chain imbalance produces a genuinely different clinical picture depending on how much normal globin chain is still being made — this classification (trait/minor, NTDT/intermedia, major/TDT) is the single most management-relevant fact in the whole chapter.
Transfusion-dependent thalassemia (beta-thalassemia major, and severe HbE/beta-thalassemia)
Presents with pallor, hepatosplenomegaly, and poor growth/anorexia alongside a microcytic, hypochromic anemia with normal ferritin and iron studies — a combination that should immediately suggest thalassemia rather than iron-deficiency anemia. Onset is from birth in alpha-thalassemia forms and typically age 3-6 months in beta-thalassemia, as protective fetal hemoglobin production declines. Without regular transfusion, roughly 85% of patients with beta-thalassemia major die before age five.[3][2]
Non-transfusion-dependent thalassemia (NTDT: beta-thalassemia intermedia, HbH disease, HbE/beta-thalassemia)
Presents with pallor, hepatosplenomegaly, +/- jaundice, and sometimes visible over-expansion of the skull and facial bones in an older infant or child — again with a hypochromic, microcytic anemia and normal ferritin/iron studies. Alternatively, an individual with a hypochromic, microcytic anemia, splenomegaly, and an elevated reticulocyte count should raise suspicion for HbH disease; some patients present with unexplained hemolytic and microcytic anemia (jaundice, dark urine, +/- gallstones), and others are picked up incidentally. Baseline hemoglobin in NTDT commonly runs 70-90 g/L.[3][4]
Trait/carrier (silent or minor)
Usually entirely asymptomatic. Unexplained microcytosis without anemia, or a hypochromic microcytic anemia in the absence of iron deficiency, should prompt investigation for a carrier (heterozygous) state — its main clinical relevance is genetic counseling, not treatment.[3]
The classic, genuinely testable consequence of inadequate transfusion is extramedullary hematopoiesis and its bony/facial changes. When compensatory erythroid marrow hyperplasia is not adequately suppressed by transfusion, marrow expansion causes bony pain, low bone density, and progressive skeletal deformities, and hematopoietic tissue can activate at extramedullary sites — producing frontal bossing, zygomatic bone prominence, a depressed nasal bridge, and shortening of long bones, exacerbating hepatosplenomegaly, and occasionally forming benign paraspinal hematopoietic pseudotumours with a real risk of spinal cord compression (see Red Flags & Refer). Maintaining a nadir hemoglobin of approximately 90-100 g/L through regular transfusion keeps the erythroid mass to only 1-4 times normal, which is what actually prevents these changes — this is the direct clinical link between the transfusion target in Choose Initial Treatment and the deformities described here.[2]
Risk Factors
- Autosomal recessive inheritance — both biological parents must carry at least one abnormal globin-gene allele for a child to be affected by a transfusion-dependent form; a child of two carriers has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither variant.[3]
- Ethnic background from a high-risk region: North Africa, the Mediterranean, the Middle East, India, Southeast Asia, and China.[3]
- A known carrier parent, or a first-degree relative with confirmed thalassemia — the specific, practical reason preconception and prenatal screening exist (see Assessment & Diagnosis).[3]
- For the bony/facial complications of extramedullary hematopoiesis specifically: inadequate or delayed transfusion, lower baseline hemoglobin, and lower fetal hemoglobin (HbF) levels.[2]
- For iron-overload complications: chronic transfusion in TDT; in NTDT, chronically decreased hepcidin driven by ineffective erythropoiesis and anemia, which increases intestinal iron absorption via ferroportin to roughly 2-4 times the normal rate even without any transfusion at all.[4]
- For thromboembolic events (more common in NTDT than TDT): splenectomy, age over 35 years, serum ferritin over 1000 ng/mL, and hemoglobin under 90 g/L.[4]
- For pulmonary hypertension: splenectomy, hydroxyurea-naive and chelation-naive status, transfusion-naive status, prior thromboembolic event, and hypoxia — again disproportionately an NTDT risk.[4]
Red Flags & Refer
Treat any of the following as a genuine emergency or urgent-referral situation, never routine reassurance:
- Fever in an asplenic patient (splenectomized, or functionally asplenic from thalassemia itself) — real risk of overwhelming sepsis from encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis); needs immediate assessment and, per NACI-based asplenia guidelines, urgent antibiotics rather than a wait-and-see approach.[5]
- New back pain, neurologic symptoms, or bowel/bladder changes — suspect a paraspinal extramedullary hematopoietic pseudotumour causing spinal cord compression; these account for roughly 11-15% of extramedullary hematopoietic pseudotumours and are a genuine neurosurgical/hematologic emergency, not simply "bone pain."[4]
- A significant, acute drop in hemoglobin, especially after a recent viral illness — suspect an aplastic crisis (classically parvovirus B19-triggered transient marrow aplasia); send parvovirus IgM and maintain hemoglobin above roughly 70 g/L while investigating. A drop associated with signs of hemolysis (worsening jaundice, dark urine) instead suggests a hemolytic crisis — hydrate, monitor renal function/electrolytes, and maintain hemoglobin in the 70-90 g/L range while looking for a bacterial or parasitic trigger.[4]
- Severe left-upper-quadrant pain, an enlarging abdominal mass, or early satiety with massive splenomegaly — risk of splenic rupture; urgent surgical assessment.[4]
- New dyspnea, reduced exercise tolerance, or signs suggestive of pulmonary hypertension — genuinely more common in NTDT than TDT; refer for echocardiography (tricuspid regurgitant jet velocity) and cardiology/pulmonary hypertension assessment.[4]
- Signs of a thromboembolic event (unilateral limb swelling, sudden dyspnea/pleuritic chest pain, focal neurologic deficit) — a genuinely elevated risk in thalassemia, especially splenectomized NTDT patients, where roughly 4-14% develop a venous thromboembolic event.[4]
- Signs of cardiac dysfunction (new arrhythmia, exertional dyspnea, edema) in a transfusion-dependent patient — cardiac iron deposition is the leading cause of death in inadequately chelated TDT; do not attribute new cardiac symptoms to deconditioning without cardiac and iron-status assessment.[6]
- New hearing loss, tinnitus, or visual changes in a patient on deferoxamine — dose-related ototoxicity/retinal toxicity; hold the drug and refer for audiometry/ophthalmology.[6]
- Fever or sore throat in a patient on deferiprone — could signal agranulocytosis; obtain an immediate CBC with differential and hold the drug pending results, regardless of how mild the infection looks.[6]
Assessment & Diagnosis
Classification
| Category | Genotype (typical) | Clinical severity |
|---|---|---|
| Alpha-thalassemia silent carrier | One of four alpha-globin genes deleted/mutated | Clinically asymptomatic |
| Alpha-thalassemia minor/trait | Two alpha-globin genes deleted/mutated | Mild microcytic anemia, usually asymptomatic |
| Hemoglobin H (HbH) disease | Three alpha-globin genes deleted/mutated (one gene intact) | NTDT — moderate hemolytic anemia; deletional forms milder, non-deletional forms (e.g. Hb Constant Spring) more severe |
| Hb Barts hydrops fetalis | All four alpha-globin genes deleted/mutated | Fatal in utero without aggressive intrauterine transfusion; survivors need lifelong TDT-equivalent transfusion support |
| Beta-thalassemia trait/carrier | One mutated beta-globin gene | Mild, clinically asymptomatic microcytosis |
| Beta-thalassemia intermedia (NTDT), incl. HbE/beta-thalassemia | Compound heterozygous milder mutations, or a thalassemic hemoglobin variant (HbE) or alternative mutation (delta-beta) | NTDT — variable, may need occasional or eventually chronic transfusion |
| Beta-thalassemia major (TDT) | Homozygous or compound heterozygous severe mutations | Severe — regular lifelong transfusion required from infancy |
The clinical phenotype cannot always be accurately predicted from genotype alone — co-inheritance of alpha-thalassemia mutations and residual fetal hemoglobin production can meaningfully modify severity, so a newly diagnosed infant needs close clinical follow-up (at least monthly) until the phenotype is truly established, rather than a genotype-based label being treated as final on day one.[7]
Diagnostic testing
- Complete blood count with red blood cell indices and a peripheral blood smear.
- Reticulocyte count — helps distinguish ineffective erythropoiesis from a primarily hemolytic picture, and is essential when an aplastic or hemolytic crisis is suspected.
- Serum ferritin — part of the initial screen; a normal ferritin alongside microcytic anemia is a genuine clue pointing away from iron deficiency and toward thalassemia.
- Hemoglobinopathy investigation — hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), or capillary zone electrophoresis (CZE).
- Molecular genetic (genotype) analysis of both alpha- and beta-globin genes — the confirmatory test, and the only way to reliably distinguish some genotypes (e.g., beta-thalassemia from the more benign HbE/beta-thalassemia or HbEE, which show the same "FE" pattern on HPLC alone).[3]
- Parents and siblings should be tested if not previously done, both to confirm the diagnosis and to begin family/genetic counseling.[7]
Newborn, preconception, and prenatal screening
Several Canadian provinces and territories — Ontario, Quebec, British Columbia, PEI, Nova Scotia, New Brunswick, Yukon, and Nunavut — have newborn screening (by HPLC) that can detect significant thalassemia syndromes (beta-thalassemia major, HbH disease, HbE/beta-thalassemia) alongside other hemoglobinopathies; screening is not yet universal across the country, and Canada's ongoing immigration from high-risk regions means a first presentation can still be a previously undiagnosed infant, child, or adult. A newborn-screening finding of Hb F only, or Hb A2 under 1.5%, identifies most babies with beta-thalassemia major; Hb Bart's over 25% suggests HbH disease. Any positive screen needs prompt confirmatory molecular testing and referral to a pediatric hematology/genetics centre.[3]
Per the Society of Obstetricians and Gynaecologists of Canada's guidance: prospective parents from high-risk regions should be screened before conception (CBC with indices, ferritin, hemoglobinopathy investigation); if both are found to be heterozygotes, genetic counseling is recommended, ideally before conception or as early as possible in pregnancy. Prenatal diagnosis (chorionic villus sampling or amniocentesis, with informed consent) should be offered to a couple at risk of an affected fetus; for those at risk of Hb Barts hydrops fetalis specifically, serial fetal ultrasound assessing the fetal cardiothoracic ratio (normal under 0.5) allows earlier identification of an affected fetus when invasive testing is declined or pregnancy presents after 20 weeks.[3]
Treatment Targets
- In TDT: maintain a pre-transfusion hemoglobin of approximately 90-100 g/L to suppress erythroid marrow expansion and prevent growth retardation, extramedullary hematopoiesis, and the resulting bony/facial deformities.[2]
- In NTDT: avoid basing the transfusion decision on hemoglobin level alone — individualize around growth, symptoms, and the specific complications below.[2]
- Detect and treat iron overload before irreversible organ damage occurs — iron overload is the dominant cause of morbidity and mortality in inadequately chelated transfused patients, and is a real, if slower-developing, risk in NTDT as well from increased intestinal absorption alone.[6][4]
- Prevent, screen for, and manage the major end-organ complications of chronic anemia and iron overload: cardiac, hepatic, endocrine, and skeletal.
- Prevent infection in a splenectomized or functionally asplenic patient.
- Support informed reproductive decisions through genetic counseling and complete first-degree relative/family cascade screening.
- Evaluate curative options (allogeneic stem cell transplant, and where appropriate gene therapy) at the right point in a patient's life — ideally discussed, and pursued if appropriate, before puberty to maximize the chance of preserving fertility.[8]
- Provide culturally appropriate, language-accessible education and psychosocial support to the patient and family from the point of diagnosis onward.[7]
Choose Initial Treatment
Start a regular transfusion program once TDT is diagnosed, targeting a pre-transfusion hemoglobin of 90-100 g/L, approximately every 3-4 weeks. Do not routinely transfuse above 100 g/L ("supertransfusion") — this only accelerates iron loading and should be reserved as a short-term strategy specifically to shrink extramedullary hematopoietic pseudotumours, not used as a general target.[2]
The decision to transfuse a patient with NTDT should not be based purely on hemoglobin level. Consider routine transfusion support for growth failure, poor school performance/developmental concerns, delayed puberty, bone deformities, symptomatic anemia with reduced exercise tolerance, or rapid splenic enlargement (over 3 cm/year) with a falling hemoglobin — and for primary or secondary prevention of specific NTDT complications (pulmonary hypertension, chronic leg ulceration, thrombotic/cerebrovascular disease, extramedullary hematopoietic pseudotumours) in high-risk patients. If routine transfusion is started, re-evaluate the response at 6 months; if no benefit is seen in either symptoms or objective organ-dysfunction measures, discontinuation (with a tapering schedule) is reasonable.[2][4]
In TDT: start chelation after approximately 10-20 transfusions, or when liver iron concentration (LIC) reaches ≥5 mg Fe/g dry weight, or ferritin is persistently over 1000 µg/L. Deferasirox is the preferred chelator for most patients. In NTDT: consider starting chelation at age 10 or older with an LIC of ≥5 mg Fe/g dry weight, beginning at half the usual TDT starting dose (e.g., deferasirox dispersible tablets 10 mg/kg/day) and adjusting to LIC/ferritin response at 6 months.[6][4]
Give folic acid supplementation to essentially every patient with NTDT or TDT, reflecting the chronically high red cell turnover common to both.[4]
Non-Pharmacologic Treatment
Splenectomy — restrictive indications, not a routine intervention
Splenectomy can reduce transfusion requirements in TDT by roughly 30%, but it is not a routine or early intervention given its own real risks (infection, thromboembolism). It should be reserved for specific situations:[2][4]
- Worsening anemia with poor growth/development where chronic transfusion or adequate iron chelation is not otherwise achievable.
- Hypersplenism with worsening cytopenias causing clinical problems such as bleeding or infection.
- Massive splenomegaly with risk of splenic rupture, significant left-upper-quadrant pain, or early satiety.
- In TDT, a total annual transfusion requirement exceeding roughly 200 mL/kg/year of pure red cells (about 5-6 units/month for a 70 kg adult) that cannot be reduced by adjusting the pre-transfusion hemoglobin target.[2]
Pre- and post-splenectomy infection prevention
- Complete NACI-recommended vaccination before a planned splenectomy — the enhanced schedule against encapsulated organisms (pneumococcal, meningococcal, Hib) on top of the routine schedule.[5]
- Provide explicit asplenia fever counseling: any fever after splenectomy is a genuine medical emergency requiring immediate assessment, never a wait-and-see approach.[5]
- Based on expert opinion (evidence for routine post-splenectomy thromboprophylaxis is otherwise lacking), consider low-dose aspirin in a splenectomized NTDT patient with a platelet count over 500 x 10⁹/L.[4]
Comprehensive, multidisciplinary care
- Care is best delivered through a comprehensive thalassemia program with prompt referral of any newly diagnosed infant/child to a pediatric hematologist, alongside access to endocrinology, hepatology, cardiology, a dietitian, and dental/orthodontic services as complications arise.[7][5]
- Discuss diagnosis and management with the family in an open, sensitive, and culturally appropriate manner — with interpreter access if English or French is not the family's primary language — and provide a written summary of the diagnosis and treatment plan to the family and their primary care provider.[7]
- Offer information on regional support groups; psychosocial support matters given the real, lifelong burden of a chronic transfusion/chelation regimen.[7]
Nutrition and dentition
- Arrange regular multidisciplinary nutritional assessment, ideally including a dietitian — patients with TDT are known to have inadequate intake of fat-soluble vitamins (A, D, E, K) and low folate, B6, thiamine, calcium, magnesium, and zinc, several of which are directly tied to bone health.[5]
- Offer regular dental and orthodontic assessment — craniofacial bone changes from inadequate/delayed/late-initiated transfusion can affect dentition and cause malocclusion.[5]
- Encourage regular weight-bearing, low-impact exercise and smoking cessation specifically for bone health.[9]
Genetic counseling and family screening
- Offer genetic counseling to patients and at-risk reproductive partners, ideally before conception; discuss prenatal diagnosis options (chorionic villus sampling or amniocentesis) for an at-risk pregnancy.[3]
- Test parents and siblings of a newly diagnosed patient if not already done.[7]
- A patient who has undergone stem cell transplant or gene therapy should still be counselled that they will pass a mutant thalassemia gene to each of their children — the corrected/donor cells address the patient's own blood production, not the germline.[8][10]
Transfusion practice specifics
- Extended red cell phenotyping (or genotyping) before the first transfusion, with prophylactic matching for C, E, c, e, and K antigens — roughly 15-20% of thalassemia patients become alloimmunized to minor blood group antigens, with even higher rates in patients of Asian descent, and prophylactic matching meaningfully reduces this.[2]
- Irradiation is reserved for specific at-risk recipients (intrauterine transfusion, a known blood relative as donor, stem cell transplant recipients, HLA-selected/homozygous platelet recipients) — asplenia in thalassemia is not by itself sufficient justification for irradiating blood products.[2]
- CMV-seronegative products are not routinely needed for thalassemia transfusion, except in pregnancy, stem cell transplant candidacy, or intrauterine transfusion.[2]
Special Populations
Pregnancy
NTDT patients may need occasional transfusion during pregnancy for an anticipated or acute hemoglobin drop; TDT patients continue their regular transfusion program with folic acid throughout. Pregnant patients with thalassemia are at increased risk of CMV and varicella infection, and CMV-seronegative blood products are indicated for transfusion during pregnancy.[2][5] Hydroxyurea is contraindicated in pregnancy.[4] Deferiprone is contraindicated in pregnancy and lactation; deferoxamine is contraindicated in the first trimester; chelation is generally deferred or individualized by the treating specialist for the remainder of pregnancy given limited safety data.[6] If a patient's mother becomes pregnant with an affected sibling under consideration for future stem cell transplant, prenatal diagnosis (CVS or amniocentesis) can be discussed, and if the fetus does not have beta-thalassemia, cord blood can be harvested and stored for potential future transplant use.[8]
Pediatrics
A newly diagnosed infant needs monthly assessment until the clinical phenotype is established, since genotype does not always accurately predict severity.[7] Growth (height, weight, growth velocity) should be monitored and plotted on ethnicity-appropriate growth charts at every visit; bone mineral density screening (DEXA) begins at age 10-12; Tanner staging begins at age 10, with delayed puberty (no breast budding by 13 in girls, no testicular enlargement by 14 in boys) prompting an endocrine workup.[9][4]
Curative options — allogeneic stem cell transplant
Allogeneic hematopoietic stem cell transplant (HSCT) is the only long-established cure for thalassemia major. With a fully HLA-matched donor (related or unrelated) and full-intensity conditioning, overall survival ranges from 91-98% and disease-free survival from 83-95%, largely independent of pre-transplant organ-complication risk class; outcomes are meaningfully better in children than in adults, and discussion should begin while the patient is young — ideally before puberty, to maximize the chance of preserving fertility.[8] For patients without an HLA-matched donor, haploidentical-donor transplant with modern conditioning protocols has recently achieved outcomes (overall and event-free survival around 96% in children up to age 19) approaching those of matched-donor transplant. Sterility/gonadal deficiency occurs in roughly 60% of patients after full-conditioning HSCT, lower in those transplanted before puberty — fertility preservation (ovarian or testicular tissue banking in prepubertal children) should be part of pre-transplant planning. After HSCT, pre-existing iron overload should continue to be addressed by routine phlebotomy (with or without chelation), targeting a ferritin under 300 µg/L.[8]
Curative options — gene therapy
Gene therapy corrects the patient's own hematopoietic stem cells (collected by apheresis) rather than replacing them with a donor's, avoiding the need for an HLA-matched donor and its graft-versus-host-disease risk — but it still requires high-dose conditioning chemotherapy to clear the native bone marrow before the corrected cells are infused, carrying the same fertility and (theoretical, not yet observed in thalassemia gene therapy) secondary-malignancy considerations as HSCT.[10] Exagamglogene autotemcel (Casgevy), a CRISPR/Cas9 gene-edited autologous cell therapy that reactivates fetal hemoglobin production, is Health Canada-approved for transfusion-dependent beta-thalassemia in patients 12 years of age and older — a genuine, currently accessible (though highly specialized, limited-centre) Canadian option, distinct from the older lentiviral gene-addition approach.[11] Betibeglogene autotemcel (Zynteglo), a lentiviral vector-based gene-addition therapy, holds FDA approval (2022) and previously held an EU conditional marketing authorization that its manufacturer voluntarily withdrew from the EU market in 2021 for commercial reasons — no Health Canada approval has been identified, so it should not be presented to a Canadian patient as a currently accessible option. Regardless of technique, patients undergoing gene therapy must be counselled that the correction applies only to their blood-forming cells, not their egg or sperm cells — they will still pass a mutant thalassemia gene to each of their children.[10]
Monitoring & Follow-Up
Transfusion-dependent thalassemia (TDT)
- Serial hemoglobin around each transfusion; serum ferritin every 3 months.[6]
- Liver iron concentration (LIC) by validated MRI after approximately 10-20 transfusions and before starting chelation, then every 6-24 months as clinically indicated.[6]
- Cardiac MRI T2* starting at age 6 (or earlier, with sedation/anesthesia if needed, since cardiac iron can accumulate by this age in chronically transfused patients), repeated every 6-24 months — myocardial T2* under 25 ms (normal is over 42 ms) predicts progressive decline in left ventricular ejection fraction, and there is no adequate non-MRI surrogate; every thalassemia patient in Canada should have access to cardiac MRI iron assessment.[6]
- Chelator-specific toxicity monitoring — see Drug Tables for the full detail by agent (deferoxamine: annual audiometry/ophthalmology, biannual growth assessment in children, baseline and periodic screening x-rays; deferasirox: baseline then monthly renal function/urinalysis/liver enzymes/CBC, then every 1-3 months once stable, annual audiometry/ophthalmology; deferiprone: weekly CBC with differential, monthly ALT for 3-6 months then every 3 months).[6]
- Annual hepatitis B and C serology in transfused patients.[5]
Non-transfusion-dependent thalassemia (NTDT)
- Iron burden screening by MRI (e.g., T2*) beginning by age 10 — this can be delayed to age 15 in deletional HbH disease, which accumulates iron more slowly.[4]
- Once chelation is started: imaging yearly, serum ferritin every 3 months; discontinue chelation once LIC falls under 3 mg Fe/g dry weight, or ferritin under 300 µg/L if MRI is unavailable.[4]
- Annual echocardiogram (tricuspid regurgitant jet velocity) for pulmonary hypertension screening.[4]
- Liver enzymes/function every 6 months from age 10; consider transient elastography for fibrosis if LIC ≥5 mg Fe/g dry weight or ferritin ≥800 ng/mL.[4]
Applies to both TDT and NTDT
- Growth parameters (height, weight, growth velocity) at every visit in children, plotted on ethnicity-appropriate charts.[9]
- Bone mineral density by DEXA (spine and hip; radius/ulna in NTDT) starting at age 10-12.[9][4]
- Annual Tanner staging from age 10, with an endocrine panel (free T4, TSH, calcium, phosphate, vitamin D, fasting glucose) checked annually from age 10.[4]
- Annual abdominal ultrasound to screen for gallstones.[4]
- Post-HSCT: close monitoring for at least the first 2 years, including management of pre-existing iron overload by phlebotomy targeting ferritin under 300 µg/L.[8]
Common Errors to Avoid
- Diagnosing or excluding iron overload from serum ferritin alone rather than MRI-based LIC and cardiac T2* — ferritin correlates poorly with myocardial iron, and in NTDT specifically it systematically underestimates true liver iron burden.[6][4]
- Basing the NTDT transfusion decision purely on hemoglobin level rather than the full clinical and complication picture — patients with HbE/beta-thalassemia in particular can tolerate severe-looking anemia well due to a right-shifted oxygen dissociation curve.[2]
- Routinely "supertransfusing" a TDT patient above a pre-transfusion hemoglobin of 100 g/L — this only accelerates iron loading and should be reserved for short-term pseudotumour-shrinkage protocols.[2]
- Treating microcytic anemia with normal ferritin/iron studies as iron-deficiency anemia and giving empiric iron — patients with thalassemia are not iron deficient, and inappropriate supplementation on top of chronic hemolysis (and, in transfused patients, transfusional loading) risks worsening iron overload.
- Performing splenectomy as an early or routine intervention rather than reserving it for the specific, restrictive indications — and failing to complete pre-splenectomy vaccination or post-splenectomy fever counseling.[4][5]
- Using high-dose deferoxamine when ferritin is already low — keep the therapeutic index (mean daily dose ÷ ferritin) under 0.025 to limit ototoxicity/retinal toxicity risk.[6]
- Missing deferiprone-associated agranulocytosis by skipping weekly CBC with differential, particularly in the first 6 months of therapy.[6]
- Assuming a "milder" phenotype can never need urgent attention — deletional HbH disease patients can still decompensate acutely with infection, oxidative stress, surgery, or pregnancy, and NTDT patients accumulate real iron overload and develop genuine complications even without ever being transfused.[2][4]
- Overlooking genetic counseling and first-degree relative/reproductive-partner testing once a diagnosis is confirmed.[3]
- Presenting a newer disease-modifying option (luspatercept, exagamglogene autotemcel) as available or appropriate for every patient without confirming current Health Canada approval status and the specific eligibility criteria (age, genotype, transfusion status) that actually apply.[11][12]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Iron chelation therapy
Doses are adult doses unless stated and require patient-specific confirmation, including renal/hepatic adjustment. NTDT dosing differs meaningfully from TDT dosing — see the NTDT-specific note in each row.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Deferasirox (dispersible tablets, Exjade; film-coated tablets, Jadenu) | TDT, dispersible tablets: 10-40 mg/kg/day TDT, film-coated tablets: 7-24 mg/kg/day NTDT (age ≥10, LIC ≥5 mg Fe/g dry weight): Start at half the usual TDT starting dose (~10 mg/kg/day dispersible tablets); adjust to LIC/ferritin at 6 months | GI symptoms (~26%), skin rash (~7%), cytopenias, rising serum creatinine/other renal effects (~34%, more common at low iron burden) | Reduces absorption of concurrent oral iron; interacts with UGT1A1 substrates; increased nephrotoxicity risk with concurrent NSAIDs | Preferred chelator for most TDT patients; the most widely used chelator in North America. Film-coated tablets have a better GI tolerability profile than dispersible tablets. Administration with food increases absorption; BID dosing can reduce GI side effects.[6] |
| Deferiprone | Adults/children: 75-100 mg/kg/day in 3 divided doses; higher end of range preferred as monotherapy | Agranulocytosis (under 2%, most likely in the first 6 months) — requires weekly CBC with differential; milder neutropenia (~8%); arthropathy; transient ALT elevation; GI upset | Avoid combining with other agents independently associated with neutropenia | First oral chelator approved in Canada (Health Canada, February 2015). Preferred cardiac chelator given superior myocardial iron penetration and more rapid T2*/LVEF improvement than deferoxamine, though it chelates the liver less efficiently. Contraindicated with a history of agranulocytosis, and in pregnancy/lactation.[6] |
| Deferoxamine (Desferal) | Children: 20-40 mg/kg/day, subcutaneous or IV, 8-12 hours, 5-7 nights/week Adults: Up to 50 mg/kg/day, subcutaneous or IV, 8-12 hours, 5-7 nights/week Aggressive chelation: Continuous IV infusion, over 50 mg/kg/day, maximum 6 g/24 hours | Ototoxicity (sensorineural hearing loss, tinnitus), retinal toxicity/night blindness/visual field changes, growth retardation (especially under age 6 or at high dose), local injection-site reactions, divalent-ion (e.g., zinc) deficiency, rare renal/pulmonary toxicity or hypotension with rapid high-dose IV use | Avoid high-dose use when ferritin is low — keep the therapeutic index (mean daily mg/kg dose ÷ serum ferritin in µg/L) under 0.025 | Historically the first available chelator; still used for aggressive chelation (continuous IV infusion) or when oral agents are not tolerated/available. Requires a portable infusion pump for practical outpatient subcutaneous dosing; administration burden is a genuine, common adherence barrier. Contraindicated in the first trimester of pregnancy.[6] |
Adjunct and disease-modifying therapy
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Folic acid | Adults and children: 1 mg PO once daily | Generally well tolerated | None clinically significant at this dose | Give to essentially every patient with NTDT or TDT given chronically high red cell turnover, not only those with a documented deficiency. |
| Luspatercept | Adults: Subcutaneous injection every 3 weeks, dose titrated per product monograph based on response | Bone/joint pain, fatigue, hypertension, hypersensitivity reactions | None clinically significant established at standard use | Health Canada-approved specifically for adults with transfusion-dependent beta-thalassemia to reduce red cell transfusion burden; an erythroid maturation agent, not a substitute for chelation or transfusion/iron monitoring.[12] |
| Hydroxyurea | NTDT, starting dose: 10 mg/kg/day with concomitant folic acid NTDT, maximum dose: Escalate to a maximum of 20 mg/kg/day; assess response at 6 months and discontinue if no clinical benefit | Reversible cytopenias, GI upset | Avoid live vaccines while on therapy per routine immunosuppressive-drug precautions | Off-label in select NTDT patients only, based on observational (not randomized-trial) evidence. Contraindicated in pregnancy and in hepatic or renal failure. Monitor CBC with differential, renal function, and liver enzymes.[4] |
Bone health
Vitamin D and calcium supplementation is reasonable for essentially every thalassemia patient; bisphosphonates are reserved for confirmed low bone density not responding to lifestyle/dietary optimization alone, and require endocrinology referral.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Vitamin D3 (cholecalciferol) | Adults and children: 1000-2000 IU daily, adjusted to target | Generally well tolerated at these doses | None clinically significant at this dose | Preferably from dietary sources where possible. Recheck serum 25-hydroxyvitamin D 3-4 months after starting adequate supplementation and do not repeat once an optimal level (≥75 nmol/L) is achieved.[9] |
| Calcium carbonate | Adults and children: 1200 mg elemental calcium daily, preferably from dietary sources | GI upset, constipation | Can reduce absorption of concurrently administered oral iron chelators or other medications if taken at the same time — separate dosing where practical | Combine with regular weight-bearing/resistance exercise, caffeine limitation, and smoking cessation for bone health.[9] |
| Zoledronic acid | Adults: Per product monograph, IV, specialist-directed | Acute-phase reaction, hypocalcemia, rare osteonecrosis of the jaw, renal effects | Use caution with other nephrotoxic agents | Specialist (endocrinology)-directed; avoid in women of childbearing potential given possible effects on future fetal bone health. Patients with NTDT/thalassemia intermedia may respond less well than those with TDT/major.[9] |
| Alendronate | Adults: Per product monograph, oral, specialist-directed | Esophagitis/GI irritation, rare osteonecrosis of the jaw, rare atypical femoral fracture with long-term use | Reduced absorption with concurrent calcium, iron, or antacids — separate dosing | Specialist (endocrinology)-directed oral alternative; same caution regarding women of childbearing potential.[9] |
Evidence note: Drug inventory, dosing, monitoring, and comments reflect current Canadian practice, drawn primarily from the CanHaem Consensus Statement of Clinical Care of Patients with Thalassemia in Canada (2024 revision), cross-checked for current Health Canada regulatory status against CDA-AMC reimbursement reviews for exagamglogene autotemcel and luspatercept.
References
- Introduction & Overview of Thalassemia — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, 2024 revision
- Transfusion Support in Thalassemia — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part II ch.2, 2024 revision
- Screening and Making the Diagnosis — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part I, 2024 revision
- Non-Transfusion Dependent Thalassemia (NTDT) — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part IV, 2024 revision
- Non-Hepatitis Infections, Nutrition and Dentition — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part III ch.8, 2024 revision
- Iron Overload and Chelation Therapy — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part II ch.3, 2024 revision
- Initial Management of Newly Diagnosed Infant — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part II ch.1, 2024 revision
- Hematopoietic Stem Cell Transplantation (HSCT) — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part II ch.4, 2024 revision
- Bone Complications — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part III ch.4, 2024 revision
- Gene Therapy (GT) — Canadian Hemoglobinopathy Association — Consensus Statement of Clinical Care of Patients with Thalassemia in Canada. Canadian Hemoglobinopathy Association, Part II ch.5, 2024 revision
- Reimbursement Review: Exagamglogene Autotemcel (Casgevy) — Canada's Drug Agency (CDA-AMC). CDA-AMC Reimbursement Review, 2025
- Luspatercept (Reblozyl) — Reimbursement Review — Canada's Drug Agency (CDA-AMC) / Canadian Journal of Health Technologies. Can J Health Technol, CDA-AMC Reimbursement Review
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.